# US 2023/0066066 A1 · Medical sheet

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066066 A1
- Document ID: US20230066066A1
- Status: Published application
- Kind: A1
- Application number: 17/790,451
- Filed: 2021-01-14
- Published: 2023-03-02
- Earliest claimed: 2020-01-14
- Assignees: Nippon Zoki Pharmaceutical Co., Ltd.
- Applicants: Nippon Zoki Pharmaceutical Co., Ltd.
- Inventors: Takafumi KONISHI; Mitsuru NAIKI; Toshiko UJITA; Hitoshi YAMAMOTO
- Web page: https://patentgrep.com/patent/US20230066066A1

## CPC

- D01F 6/92: of polyesters
- D01F 6/625: {derived from hydroxy-carboxylic acids, e.g. lactones}
- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/146: {Porous materials, e.g. foams or sponges}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61L 2300/428: Vitamins, e.g. tocopherol, riboflavin
- A61L 2300/604: Biodegradation
- A61L 2430/32: for nerve reconstruction
- A61P 25/00: Drugs for disorders of the nervous system
- D01F: CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A medical sheet has a cell infiltration suppressing action, including a nonwoven fabric formed of fiber containing an aliphatic polyester, and having a porosity of 50 to 90%. The sheet is very useful because it has an excellent neuroprotective and/or nerve regeneration promoting action, which protects nerves by suppressing the infiltration of inflammatory cells such as macrophages and not giving stimulation that adversely affects nerves because body fluids pass therethrough, by winding around a nerve at a peripheral nerve injury site.

## Claims

### Claim at position 1

-30. (canceled)

### Claim 31

A sheet comprising a nonwoven fabric formed of fiber containing an aliphatic polyester, wherein a porosity of the sheet is 50 to 90% and the sheet has a cell infiltration suppressing action.

### Claim 32 (depends on 31)

The sheet according to claim 31, wherein a thickness of the sheet is 30 to 70 μm.

### Claim 33 (depends on 31)

The sheet according to claim 31, wherein a weight of the sheet is 0.5 to 10 mg/cm2.

### Claim 34 (depends on 31)

The sheet according to claim 31, wherein a density of the sheet is 100 to 1000 mg/cm3.

### Claim 35 (depends on 31)

The sheet according to claim 31, wherein the fiber has an average fiber diameter of 300 to 1500 nm.

### Claim 36 (depends on 31)

The sheet according to claim 31, wherein the aliphatic polyester contained in the fiber has a molecular weight distribution in which a maximum value exists in at least two or more regions of the molecular weight.

### Claim 37 (depends on 36)

The sheet according to claim 36, wherein at least one of the regions of the molecular weight is a region of a number average molecular weight of 1000 to 7000 before sterilization treatment.

### Claim 38 (depends on 36)

The sheet according to claim 36, wherein at least one of the regions of the molecular weight is a region of a number average molecular weight of 40000 to 150000 before sterilization treatment.

### Claim 39 (depends on 36)

The sheet according to claim 36, wherein the region of the molecular weight is at least two regions of a region of a number average molecular weight of 1000 to 7000 and a region of a number average molecular weight of 40000 to 150000 before sterilization treatment.

### Claim 40 (depends on 36)

The sheet according to claim 36, wherein, when the aliphatic polyester having a maximum value on a lowest molecular weight side among the aliphatic polyesters contained in the fiber that form the nonwoven fabric is defined as a low molecular weight component, and the aliphatic polyester having a maximum value on a highest molecular weight side among the aliphatic polyesters contained in the fiber that form the nonwoven fabric is defined as a high molecular weight component, a mass ratio of a content of the low molecular weight component to a sum of a content of the low molecular weight component and a content of the high molecular weight component in the nonwoven fabric is 0.01 or more and 0.3 or less.

### Claim 41 (depends on 31)

The sheet according to claim 31, wherein the aliphatic polyester is at least one biodegradable aliphatic polyester selected from the group consisting of polycaprolactone, polycaprolactone diol, polylactic acid, polyglycolic acid, and copolymers thereof.

### Claim 42 (depends on 31)

The sheet according to claim 31, wherein the cell is an inflammatory cell.

### Claim 43 (depends on 31)

The sheet according to claim 31, wherein the sheet has further a neuroprotective and/or nerve regeneration promoting action.

### Claim 44 (depends on 43)

The sheet according to claim 43, wherein the neuroprotective and/or nerve regeneration promoting action results from suppression of neural scarring.

### Claim 45 (depends on 31)

The sheet according to claim 31, wherein the sheet contains further a drug.

### Claim 46 (depends on 45)

The sheet according to claim 45, wherein the drug is a therapeutic agent for nerve injury.

### Claim 47 (depends on 46)

The sheet according to claim 46, wherein the therapeutic agent for nerve injury is vitamin B12.

### Claim 48 (depends on 47)

The sheet according to claim 47, wherein a content of the vitamin B12 is 0.005 to 0.5 mg per 1 cm2 of the sheet.

### Claim 49 (depends on 31)

The sheet according to claim 31, wherein the sheet is used by being implanted into a periphery of a nerve injury site in a living body.

### Claim 50 (depends on 31)

The sheet according to claim 31, wherein the sheet is used by being wound around a nerve at a nerve injury site in a living body.
